# Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)

> **NCT06127225** · PHASE2 · COMPLETED · sponsor: **Dexa Medica Group** · enrollment: 80 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** Proliverenol
- **DRUG:** Placebo caplets of Proliverenol

## Key facts

- **NCT ID:** NCT06127225
- **Lead sponsor:** Dexa Medica Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-28
- **Primary completion:** 2024-08-09
- **Final completion:** 2024-08-28
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06127225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06127225, "Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06127225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*